Ticker delayed 20 minutes
Avg Daily Volume: 1,142,949 Market Cap: 1.62B Sector: Consumer Goods Short Interest: 43.11 |
EARNINGS EXPECTATIONS:
THIS QTR: EPS: .52/share REV: 259.38/M
___________________________________________________________
LAST QTR: EPS: .03/share ACTUAL: .25/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: .39/share REV: 443.9/M
______________________________________________________
FULL YR: EPS: 2.27/share REV: 1,200/M
______________________________________________________
*These are the base metrics we will be watching against the actual release numbers
______________________________________________________
BEAT/MISS RECORD: 63% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) -22.73, -23.22, 16.36
EXPECTED JUMP MOVE: 15-20%
Links To Latest News and Headlines
Between constant tracking of our internet activity, the “always listening” speakers in our homes and the smartphones glued to our hands at all (OK, most) times we’re awake, it’s understandable that nervous murmurs of George Orwell’s “1984” often come up in conversation these days. The retail giant announced it would acquire iRobot for $1.7 billion, making it Amazon’s fourth largest acquisition to date.
iRobot (IRBT) reported earnings 30 days ago. What’s next for the stock? We take a look at earnings estimates for some clues.
Magnetar Capital cut its stake in iRobot, a maker of automated cleaning devices. RA Capital disclosed a large stake in drug firm Acrivon Therapeutics.
iRobot’s (IRBT) third-quarter 2022 revenues decline 36.9% due to lower orders from retailers and distributors in North America and EMEA.
iRobot (IRBT) delivered earnings and revenue surprises of -217.88% and 36.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
StockJumpers analysis and trade plans are uploaded generally 1 HOUR (3PM EST) for most events.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
ANALYSIS:
StockJumpers trajectory analysis reveals a positive market reaction to the release news. It takes more than a beat however, last quarter they beat significantly and the stock went down on weaker guidance. We think its oversold for their potential and unless there is bad news on the horizon we see a pop up post release
We are biased long on this event.
___________________
OUR TRADE PLAN:
ENTRY: BUY – end of day or before.
STOP LOSS: NA
INITIAL PROFIT TARGET: 13%
___________________
TRADE ASSIST: TBA
POST RELEASE ACTION:
[/mepr-show
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is striped down to only what it needed to make the best possible decision(s) on trading the trajectory.
NOTICE: All data on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.